Public Health Emergency - Leading a Nation Prepared
BARDA is supporting multiple products to accelerate the development of medical countermeasures. BARDA will bring our full expertise to partners for advanced clinical trials of 2 products and secure domestic manufacturing of vaccines to prevent COVID-19.
HHS accepted and FDA issued an emergency use authorization for 30 million doses of donated medicines from Sandoz and Bayer for possible use in treating patients hospitalized with COVID-19 or for use in clinical trials. The drugs are approved for use in treating malaria and other diseases.
Hospitals and healthcare workers are on the front lines of the COVID-19 pandemic. To help them respond rapidly and safety, HHS is providing $100 million to create a National Special Pathogen System, leveraging existing public health and health care infrastructure and capabilities, as well as expertise from the U.S. Ebola response.
A rapid diagnostic test for COVID-19 has received advanced development support through a collaboration between BARDA, JPEO-CBRND, and Cepheid. The test can provide results within 45 minutes, and is designed for use in clinical and hospitals laboratories.
BARDA is supporting a Phase 2/3 clinical trial for an antibody medicine being evaluated to treat severe cases of COVID-19, which are being conducted by Regeneron. Through this public-private partnership, we are working to develop potentially life-saving therapeutics rapidly.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages